메뉴 건너뛰기




Volumn 57, Issue SUPPL. 2, 2007, Pages

Optimising survival in malignant mesothelioma

Author keywords

Diagnosis; Mesothelioma; Pemetrexed; Prognostic factors; Therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BAY 429006; BEVACIZUMAB; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; ERLOTINIB; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; MESOTHELIN; OSTEOPONTIN; PEMETREXED; PLACEBO; RALTITREXED; SEMAXANIB; SORAFENIB; SUNITINIB; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

EID: 34547516226     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(07)70424-5     Document Type: Article
Times cited : (12)

References (28)
  • 1
    • 3142741275 scopus 로고    scopus 로고
    • Epidemiology of mesothelioma
    • Robinson B., and Chahinian A. (Eds), Martin Dunitz, London
    • De Kleck N., and Musk A. Epidemiology of mesothelioma. In: Robinson B., and Chahinian A. (Eds). Mesothelioma (2002), Martin Dunitz, London 339-350
    • (2002) Mesothelioma , pp. 339-350
    • De Kleck, N.1    Musk, A.2
  • 3
    • 0031961891 scopus 로고    scopus 로고
    • Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience
    • Curran D., Sahmoud T., Therasse P., et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 (1998) 145-152
    • (1998) J Clin Oncol , vol.16 , pp. 145-152
    • Curran, D.1    Sahmoud, T.2    Therasse, P.3
  • 4
    • 1642576134 scopus 로고    scopus 로고
    • Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies
    • Coppola D., Szabo M., Boulware D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10 (2004) 184-190
    • (2004) Clin Cancer Res , vol.10 , pp. 184-190
    • Coppola, D.1    Szabo, M.2    Boulware, D.3
  • 5
    • 33646587019 scopus 로고    scopus 로고
    • Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma
    • Scherpereel A., Grigoriu B., Conti M., et al. Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 175 (2006) 1155-1160
    • (2006) Am J Respir Crit Care Med , vol.175 , pp. 1155-1160
    • Scherpereel, A.1    Grigoriu, B.2    Conti, M.3
  • 6
    • 26444506232 scopus 로고    scopus 로고
    • Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
    • Pass H., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 (2005) 1564-1573
    • (2005) N Engl J Med , vol.353 , pp. 1564-1573
    • Pass, H.1    Lott, D.2    Lonardo, F.3
  • 7
    • 0017255624 scopus 로고
    • Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients
    • Butchart E., Ashcroft T., Barnsley W., et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31 (1976) 15-24
    • (1976) Thorax , vol.31 , pp. 15-24
    • Butchart, E.1    Ashcroft, T.2    Barnsley, W.3
  • 8
    • 0010061755 scopus 로고
    • Natural history and clinical staging of malignant mesothelioma
    • Mattson K. Natural history and clinical staging of malignant mesothelioma. Eur J Respir Dis 63 Suppl 124 (1982) 87
    • (1982) Eur J Respir Dis , vol.63 , Issue.SUPPL. 124 , pp. 87
    • Mattson, K.1
  • 9
    • 0010064556 scopus 로고
    • Therapeutic modalities in malignant pleural mesothelioma
    • Chretien J., and Hirsch A. (Eds), Masson, New York
    • Chahinian A. Therapeutic modalities in malignant pleural mesothelioma. In: Chretien J., and Hirsch A. (Eds). Disease of the pleura (1983), Masson, New York 224
    • (1983) Disease of the pleura , pp. 224
    • Chahinian, A.1
  • 11
    • 0027211732 scopus 로고
    • Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging
    • Boutin C., Rey F., Gouvernet J., et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72 (1993) 394-404
    • (1993) Cancer , vol.72 , pp. 394-404
    • Boutin, C.1    Rey, F.2    Gouvernet, J.3
  • 12
    • 0027285687 scopus 로고
    • Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma
    • Sugarbaker D., Strauss G., Lynch T., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (1993) 1172-1178
    • (1993) J Clin Oncol , vol.11 , pp. 1172-1178
    • Sugarbaker, D.1    Strauss, G.2    Lynch, T.3
  • 13
    • 0028825114 scopus 로고
    • A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group
    • Rusch V. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
    • (1995) Chest , vol.108 , pp. 1122-1128
    • Rusch, V.1
  • 14
    • 0031887839 scopus 로고    scopus 로고
    • Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
    • Herndon J., Green M., Chahinian A., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
    • (1998) Chest , vol.113 , pp. 723-731
    • Herndon, J.1    Green, M.2    Chahinian, A.3
  • 15
    • 0033849171 scopus 로고    scopus 로고
    • Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
    • Edwards J., Abrams K., Leverment J., et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55 (2000) 731-735
    • (2000) Thorax , vol.55 , pp. 731-735
    • Edwards, J.1    Abrams, K.2    Leverment, J.3
  • 16
    • 33746875641 scopus 로고    scopus 로고
    • A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer
    • Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355 (2006) 570-580
    • (2006) N Engl J Med , vol.355 , pp. 570-580
    • Potti, A.1    Mukherjee, S.2    Petersen, R.3
  • 18
    • 0029928641 scopus 로고    scopus 로고
    • Chemotherapy in malignant pleural mesothelioma. A review
    • Ong S., and Vogelzang N. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 14 (1996) 1007-1017
    • (1996) J Clin Oncol , vol.14 , pp. 1007-1017
    • Ong, S.1    Vogelzang, N.2
  • 19
    • 0023840760 scopus 로고    scopus 로고
    • Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres
    • Albert A., Falkson G., Goedhals L., et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres. J Clin Oncol 6 (1998) 527-535
    • (1998) J Clin Oncol , vol.6 , pp. 527-535
    • Albert, A.1    Falkson, G.2    Goedhals, L.3
  • 20
    • 0036837690 scopus 로고    scopus 로고
    • Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis
    • Berghmans T., Paesmans M., Lalami Y., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis. Lung Cancer 38 (2002) 111-121
    • (2002) Lung Cancer , vol.38 , pp. 111-121
    • Berghmans, T.1    Paesmans, M.2    Lalami, Y.3
  • 21
    • 0041629528 scopus 로고    scopus 로고
    • Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    • Vogelzang N., Rusthoven J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
    • (2003) J Clin Oncol , vol.21 , pp. 2636-2644
    • Vogelzang, N.1    Rusthoven, J.2    Symanowski, J.3
  • 22
    • 27744476091 scopus 로고    scopus 로고
    • Standard therapy for the treatment of malignant pleural mesothelioma
    • Vogelzang N. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 50 Suppl 1 (2005) S23-S24
    • (2005) Lung Cancer , vol.50 , Issue.SUPPL. 1
    • Vogelzang, N.1
  • 23
    • 27244447448 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
    • van Meerbeeck J., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
    • (2005) J Clin Oncol , vol.23 , pp. 6881-6889
    • van Meerbeeck, J.1    Gaafar, R.2    Manegold, C.3
  • 24
    • 33645449947 scopus 로고    scopus 로고
    • Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    • Ceresoli G., Zucali P., Favaretto A., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 (2006) 1443-1448
    • (2006) J Clin Oncol , vol.24 , pp. 1443-1448
    • Ceresoli, G.1    Zucali, P.2    Favaretto, A.3
  • 25
    • 31544441696 scopus 로고    scopus 로고
    • A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial
    • O'Brien M., Watkins D., Ryan C., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17 (2006) 270-275
    • (2006) Ann Oncol , vol.17 , pp. 270-275
    • O'Brien, M.1    Watkins, D.2    Ryan, C.3
  • 26
    • 34547549701 scopus 로고    scopus 로고
    • A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)
    • Jassem J., Ramlau R., Santoro A., et al. A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM). Ann Oncol Suppl 9 (2006) ix214
    • (2006) Ann Oncol , Issue.SUPPL. 9
    • Jassem, J.1    Ramlau, R.2    Santoro, A.3
  • 27
    • 0026608650 scopus 로고
    • Correlation of basic fibroblast growth factor expression levels with degree of malignancy and vascularity in human gliomas
    • Takahashi J., Fukumoto M., Igarashi K., et al. Correlation of basic fibroblast growth factor expression levels with degree of malignancy and vascularity in human gliomas. J Neurosurg 76 (1992) 792-798
    • (1992) J Neurosurg , vol.76 , pp. 792-798
    • Takahashi, J.1    Fukumoto, M.2    Igarashi, K.3
  • 28
    • 0025201337 scopus 로고
    • Immunohistochemical localization of basic fibroblast growth factor in astrocytomas
    • Zagzag D., Miller D., Sato Y., et al. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50 (1990) 7393-7398
    • (1990) Cancer Res , vol.50 , pp. 7393-7398
    • Zagzag, D.1    Miller, D.2    Sato, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.